Genenta Science Files 6-K on Agreement Amendment
Ticker: GNTA · Form: 6-K · Filed: Dec 30, 2024 · CIK: 1838716
| Field | Detail |
|---|---|
| Company | Genenta Science S.P.A. (GNTA) |
| Form Type | 6-K |
| Filed Date | Dec 30, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: agreement-amendment, sec-filing, registration-statement
TL;DR
Genenta Science amended a key development agreement, filing it with the SEC.
AI Summary
Genenta Science S.p.A. filed a Form 6-K on December 30, 2024, reporting a Second Amendment to its Development and Master Services Agreement. This filing is incorporated by reference into the company's registration statement on Form F-3 (File No. 333-271901).
Why It Matters
Amendments to key agreements can impact a company's development timelines, costs, and strategic partnerships, potentially affecting its future financial performance and product pipeline.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of an agreement amendment and does not appear to contain significant new financial or operational risks.
Key Players & Entities
- Genenta Science S.p.A. (company) — Registrant
- 333-271901 (dollar_amount) — Form F-3 File Number
FAQ
What is the specific nature of the Second Amendment to the Development and Master Services Agreement?
The filing does not provide specific details about the content of the Second Amendment, only that it has been executed.
When was the Second Amendment to the Development and Master Services Agreement effective?
The filing indicates the amendment is effective as of the reporting date, December 30, 2024.
What is the purpose of incorporating this 6-K into the Form F-3 registration statement?
Incorporation by reference makes the information in the 6-K part of the registration statement, providing investors with updated or relevant information about the company.
What is Genenta Science S.p.A.'s primary business?
Genenta Science S.p.A. is in the business of Biological Products (no diagnostic substances).
Where is Genenta Science S.p.A. headquartered?
Genenta Science S.p.A. is headquartered in Milan, Italy.
Filing Stats: 572 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2024-12-30 16:05:26
Filing Documents
- form6-k.htm (6-K) — 22KB
- ex10-1.htm (EX-10.1) — 60KB
- 0001493152-24-052474.txt ( ) — 83KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GENENTA SCIENCE S.P.A. By: /s/ Richard B. Slansky Name: Richard B. Slansky Title: Chief Financial Officer Dated: December 30, 2024